AbbVie and Abbott under StockCall Scrutiny: Major Drug Manufacturers Look to Emerging Economies

 AbbVie and Abbott under StockCall Scrutiny: Major Drug Manufacturers Look to
                              Emerging Economies

  PR Newswire

  LONDON, January 28, 2013

LONDON, January 28, 2013 /PRNewswire/ --

Last year, the U.S. Supreme Court upheld President Obama's Affordable Care
Act, which is expected to have a significant impact on major drug
manufacturers. In order to minimize the impact of Affordable Care Act, drug
manufacturers have implemented new strategies. One such company is Abbott
Laboratories (NYSE: ABT), which recently spun off its proprietary drug
business into AbbVie (NYSE: ABBV). StockCall has compiled comprehensive
technical analysis on these two drug companies, and these reports are
available for free at 

Implications of Affordable Care Act

The Patient Protection and Affordable Care Act (PPACA), which was signed into
a law by President Obama in his first term, represent a major overhaul of the
U.S. healthcare system.

The Affordable Care Act is expected to have a significant impact on major drug
manufacturers in the U.S. While drug manufacturers can expect new business as
a result of PPACA, they are also likely to see increased costs. According to
some estimates, the act will cost drug manufacturers over $80 billion in the
next 10 years. Although higher drug sales due to expanded coverage will offset
some of these costs, it will not be sufficient. This has led major drug
companies re-think their strategy.

Abbott looks to Emerging Economies

Abbott Laboratories is looking to minimize the impact of Affordable Care Act
in the U.S. by focusing on emerging markets. Earlier last week, the
Illinois-based company reported its fourth quarter financial results.
Excluding one-time items, the company reported a profit of $1.51 per share.
Download the complete technical analysis on Abbott at 

In a conference call with analysts following the release of quarterly results,
Abbott CEO Miles D. White said that the global population is growing and
living longer and the company sees significant opportunities ahead. Mr. White
believes that the company's mix of diversified healthcare businesses and
pipeline is favorably aligned with key healthcare and emerging market trends
and well positioned to deliver top-tier growth this year.

The New Abbott

Earlier this year, Abbott completed the separation of its research-based
pharmaceutical business. The new independent biopharmaceutical company, AbbVie
Inc. [ Free Report on ABBV ] ^[ ^(1) ^] , began trading on the New York Stock
Exchange under the ticker symbol ABBV. Abbott had announced the spin off back
in October 2011 as the company's business evolved into two different
investment identities.

AbbVie will operate as a research-based specialty biopharmaceutical company.
The company already has a broad portfolio of medicines and a pipeline of
breakthrough therapies. The new Abbott, meanwhile, will focus on four
businesses, which include diagnostics, medical devices, nutritionals and
branded generic pharmaceuticals. The revenue from these businesses is well
balanced in terms of geography, with about 40% of the revenue generated from
the fastest-growing economies of the world, including Brazil, China, India and
Russia. By 2015, Abbott expects these markets to account for 50% of its sales.

Commenting on the spin-off, Mr. White earlier this month said that Abbott has
taken the most transformative action in its 125-year history. He added that
the company has had enduring success precisely because of reinventing itself
for changing times and creating new ways to serve millions of patients,
customers, communities and shareholders who depend on the company.

The new Abbott certainly is well-positioned to deliver growth.


1.AbbVie Inc. Technical Analysis [ ]

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

Contact: William T. Knight, Email:, Contact Number:
+1-646-396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.